Evidence map›Paper›PMID 37720805›Full record

ReviewDrug, healthcare and patient safety2023

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease.

Shaun O'Hagan, Niamh Galway, Michael D Shields, Peter Mallett, Helen E Groves

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug, healthcare and patient safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Chronic lung disease of prematurity and bronchopulmonary dysplasia.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024
    Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shaun O'HaganPaediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland.
Niamh GalwayPaediatric Respiratory Medicine, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland.
Michael D ShieldsPaediatric Respiratory Medicine, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland.
Peter MallettPaediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland.
Helen E GrovesPaediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific "high-risk" populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.

Indexed as

efficacyfuture directionspalivizumabRSVsafety

Identifiers

PMID37720805
PMCPMC10503506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.